Taysha Gene Therapies, Inc. (TSHA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 12 Best American Penny Stocks to Buy Right Now. On November 5, Citizens increased its price target on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ...
We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how Taysha Gene Therapies, Inc. (NASDAQ:TSHA) compares to the other top short ...
Taysha Gene Therapies' TSHA-102 tackles Rett syndrome’s root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA’s main value driver, and it appears safe and effective in both ...
Taysha Gene Therapies, Inc.’s lead asset is TSHA-102. This is an intrathecal AAV9 gene therapy for Rett with a 100% Phase 1/2 responder rate and favorable safety. The FDA granted it a Breakthrough ...
Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results